BRIEF-Selecta Announces Transition Of Manufacturing And Clinical Operations Of Immtor For Sel-212 To Commercialization Partner SOBI

Reuters2023-11-01

Oct 31 (Reuters) - Selecta Biosciences Inc :

* SELECTA ANNOUNCES TRANSITION OF MANUFACTURING AND CLINICAL OPERATIONS OF IMMTOR FOR SEL-212 TO COMMERCIALIZATION PARTNER SOBI

* SELECTA BIOSCIENCES INC - AS OF NOVEMBER 6 SOBI WILL ASSUME RESPONSIBILITY FOR MANUFACTURING AND COMMERCIAL SUPPLY OF IMMTOR FOR SEL-212

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment